Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Folashade Otegbeye

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Leukemia & Lymphoma|January 19, 2021
Efficacy and cost-benefit of filgrastim administered after early assessment bone marrow biopsy during induction therapy for acute myeloid leukemiaJiasheng Wang, Marcos de Lima, Brenda W Cooper, et al.
American Journal of Hematology|April 21, 2020
Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma - specific venous thrombosis prediction modelsGouri Dharmavaram, Shufen Cao, Suchitra Sundaram, et al.
Transplantation and Cellular Therapy|February 16, 2022
A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult DonorsFolashade Otegbeye, Brenda Cooper, Paolo Caimi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 9, 2019
Gastrointestinal Microbiome and Mycobiome Changes during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot StudyNajla El Jurdi, Ali Filali-Mouhim, Iman Salem, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 2, 2019
Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome RelapseMasumi Ueda, Najla El-Jurdi, Brenda Cooper, et al.
Frontiers in Immunology|October 29, 2021
Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin LymphomaPaolo F Caimi, Gabriela Pacheco Sanchez, Ashish Sharma, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 12, 2018
Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid LeukemiaFahrettin Covut, Divya Gupta, Raisa Pinto, et al.
Transplantation and Cellular Therapy|June 1, 2022
Natural Killer Cell Alloreactivity Predicted By Killer Cell Immunoglobulin-Like Receptor Ligand Mismatch Does Not Impact Engraftment in Umbilical Cord Blood and Haploidentical Stem Cell TransplantationFolashade Otegbeye, Marcelo A Fernandez Vina, Tao Wang, et al.
Blood Advances|January 3, 2024
A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemiaLeland L Metheny, Ronald Sobecks, Christina Cho, et al.
Haematologica|March 13, 2025
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow upAndrew J Portuguese, Jennifer J Huang, Yein Jeon, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Leukemia & Lymphoma|January 19, 2021
Efficacy and cost-benefit of filgrastim administered after early assessment bone marrow biopsy during induction therapy for acute myeloid leukemiaJiasheng Wang, Marcos de Lima, Brenda W Cooper, et al.
American Journal of Hematology|April 21, 2020
Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma - specific venous thrombosis prediction modelsGouri Dharmavaram, Shufen Cao, Suchitra Sundaram, et al.
Transplantation and Cellular Therapy|February 16, 2022
A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult DonorsFolashade Otegbeye, Brenda Cooper, Paolo Caimi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 9, 2019
Gastrointestinal Microbiome and Mycobiome Changes during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot StudyNajla El Jurdi, Ali Filali-Mouhim, Iman Salem, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 2, 2019
Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome RelapseMasumi Ueda, Najla El-Jurdi, Brenda Cooper, et al.
Frontiers in Immunology|October 29, 2021
Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin LymphomaPaolo F Caimi, Gabriela Pacheco Sanchez, Ashish Sharma, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 12, 2018
Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid LeukemiaFahrettin Covut, Divya Gupta, Raisa Pinto, et al.
Transplantation and Cellular Therapy|June 1, 2022
Natural Killer Cell Alloreactivity Predicted By Killer Cell Immunoglobulin-Like Receptor Ligand Mismatch Does Not Impact Engraftment in Umbilical Cord Blood and Haploidentical Stem Cell TransplantationFolashade Otegbeye, Marcelo A Fernandez Vina, Tao Wang, et al.
Blood Advances|January 3, 2024
A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemiaLeland L Metheny, Ronald Sobecks, Christina Cho, et al.
Haematologica|March 13, 2025
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow upAndrew J Portuguese, Jennifer J Huang, Yein Jeon, et al.
Pageof 4